A significant elevation was denoted in the expression of CCL2, CCL5, TNFα and IL-1β in the tumor cells in all groups of cancer patients (DCIS, IDC-no-relapse and IDC-with-relapse), when compared to their expression in the normal breast cells in biopsies of the Benign patients, with significance value of p < 0.001 in all cases. This evidence concerns the gene CCL5 and ductal breast carcinoma in situ.